Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer

Abstract

This cost-effectiveness study analyses the expected impacts of activities proposed by the Croatian National Plan Against Cancer (NPAC) on cancer incidence and survival rates, as related to their respective costs. We evaluated the impact of the NPAC on two main outcomes, namely, reduced incidence and the improved survival of cancer patients, expressed as life years gained (LYGs), which enabled the calculation of incremental cost-effectiveness ratios (ICERs) in the form of cost per LYG. In the analysis of costs, we considered both the direct costs of NPAC activities as well as the wider indirect societal costs of cancer, thus permitting the calculation of the ICER both from the narrower national health insurer’s perspective (accounting only for the direct costs) and the wider societal perspective (accounting both for the direct and indirect costs). We estimated that on average, for all patients benefiting from the implementation of the NPAC in Croatia, an additional LYG would be yielded at the additional cost of €1.021 (societal perspective). The NPAC can, for some sites, even be considered a dominant intervention due to the negative cost/LYG ratio, meaning that it generates additional LYGs while at the same time, reducing total societal costs. Taking a narrower health insurer’s perspective (i.e., accounting only for the direct costs), the NPAC produces an additional LYG at an additional cost of €1.408. Both cost per LYG estimates can be considered cost-effective investment options.

This is a preview of subscription content, access via your institution.

Notes

  1. 1.

    Period over which the NPAC is to be implemented.

References

  1. 1.

    Vrdoljak et. al.: National cancer control plan 2020–2030. https://www.nppr.hr/wp-content/uploads/2020/01/NPPR_ENG_final.pdf (2019). Accessed 20 Nov 2020

  2. 2.

    Eurostat. Assumptions for life expectancy by age, sex and type of projection. Available at https://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do (2019). Accessed 16 Oct 2019

  3. 3.

    The European Partnership for Action Against Cancer (EPAAC). National Cancer Plan Collection. http://www.epaac.eu/national-cancer-plans 2020. Accessed Oct 2020

  4. 4.

    Romero, Y., Trapani, D., Johnson, S., Tittenbrun, Z., Given, L., Hohman, K., Stevens, L., Torode, J.S., Boniol, M., Ilbawi, A.M.: National cancer control plans: a global analysis. Lancet Oncol 19(10), e546–e555 (2018)

    Article  Google Scholar 

  5. 5.

    Ralaidovy, A.H., Gopalappa, C., Ilbawi, A., et al.: Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE. Cost Eff Resour Alloc 16, 38 (2018)

    Article  Google Scholar 

  6. 6.

    Croatian Institute of Public Health. Croatian National Cancer Register. Cancer incidence in Croatia in 2016. Bulletin 41, Zagreb. https://www.hzjz.hr/wp-content/uploads/2017/01/Bilten-2016_zavrsna.pdf (2019). Accessed Nov 2019

  7. 7.

    Croatian Institute of Public Health. Demographic trends in Croatia in 2017. Zagreb. https://www.hzjz.hr/wp-content/uploads/2018/08/Prirodno_kretanje_2017.pdf (2018). Accessed Oct 2019

  8. 8.

    Eurostat. Cancer statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php/Cancer_statistics#Deaths_from_cancer (2015). Accessed Nov 2019

  9. 9.

    Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14, 1165–1174 (2013)

    Article  Google Scholar 

  10. 10.

    Globocan. http://gco.iarc.fr/today/data/factsheets/populations/705-slovenia-fact-sheets.pdf (2018). Accessed May 2019

  11. 11.

    Croatian bureau of statistics (CBS, 2019). https://www.dzs.hr/Hrv_Eng/publication/2019/09-01-01_05_2019.htm (2019). Accessed May 2019

  12. 12.

    Cancer Registry of Republic of Slovenia. https://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/LP_2006.pdf (2006). Accessed May 2019

  13. 13.

    Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6), 394–424 (2018)

    Article  Google Scholar 

  14. 14.

    Vrdoljak, E., Bodoky, G., Jassem, J., Popescu, R., Pirker, R., Čufer, T., Bešlija, S., Eniu, A., Todorović, V., Kopečková, K., Kurteva, G.: Expenditures on oncology drugs and cancer mortality-to-incidence ratio in central and Eastern Europe. Oncologist 24(1), e30–e37 (2019)

    Article  Google Scholar 

  15. 15.

    Vrdoljak, E., Bodoky, G., Jassem, J., Popescu, R.A., Mardiak, J., Pirker, R., Cufer, T., Bešlija, S., Eniu, A., Todorović, V., KubáčkováKurteva, K.G., Tomašević, Z., Sallaku, A., Smichkoska, S., Bajić, Z., Sikić, B.I.: Cancer control in central and eastern Europe: current situation and recommendations for improvement. Oncologist 21(10), 1183–1190 (2016)

    Article  Google Scholar 

  16. 16.

    American Cancer Society. Cancer facts and figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf (2019). Accessed Nov 2019

  17. 17.

    Office for National Statistics. https://www.nuffieldtrust.org.uk/resource/cancer-survival-rates (2019). Accessed Nov 2019

  18. 18.

    OECD. https://stats.oecd.org/Index.aspx?QueryId=51882 (2019). Accessed Nov 2019

  19. 19.

    Leal, J., Wordsworth, S., Legood, R., Blair, E.: Eliciting expert opinion for economic models: an applied example. Value Health 10(3), 195–203 (2007)

    Article  Google Scholar 

  20. 20.

    Zadnik, V., Zakelj, M.P., Lokar, K., Jarm, K., Ivanus, U., Zagar, T.: Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 51(1), 47–55 (2017)

    Article  Google Scholar 

  21. 21.

    Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C.: Cost-effectiveness in health and medicine. Oxford University Press, New York (1996)

    Google Scholar 

  22. 22.

    Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)

    Google Scholar 

Download references

Acknowledgements

We gratefully thank the current and former ministers of health of the Republic of Croatia, Dr Milan Kujundzic, PhD and Dr Vili Beros, PhD for their continued support and political leadership in the development of the National Plan Against Cancer. The work of Ana Bobinac was supported in part by the Croatian science fundation (UIP-2019-04-3721).

Funding

The work of Ana Bobinac was supported in part by the Croatian science fundation (UIP-2019-04-3721).

Author information

Affiliations

Authors

Contributions

All authors contributed to the study conception and design. The first draft of the manuscript was written by Luka Voncina, Ana Bobinac and Eduard Vrdoljak and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ana Bobinac.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vrdoljak, E., Sekerija, M., Plestina, S. et al. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. Eur J Health Econ 22, 393–403 (2021). https://doi.org/10.1007/s10198-020-01262-0

Download citation

Keywords

  • Economic evaluation
  • National plan against cancer
  • Cost per LYG
  • ICER

JEL Classification

  • I18 Government Policy
  • Regulation
  • Public Health